Most Favored Patient Act of 2026
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- House
- Sponsor
- 1
- Latest action
- Mar 5, 2026
What it does
The Most Favored Patient Act of 2026 would require the Center for Medicare and Medicaid Innovation to test a five-year model, beginning January 1, 2029, that implements most-favored-nation drug pricing by requiring specified manufacturers to provide access to the second-lowest price paid for covered drugs in select reference countries (Canada, Denmark, France, Germany, Italy, Japan, Switzerland, and the United Kingdom) to eligible Medicare and Medicaid beneficiaries and providers. The bill affects drug manufacturers without a covered agreement with the Secretary of Health and Human Services, requiring them to report pricing data and offer the most-favored-nation price to eligible…
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
In the news
Reporting that may mention this subject. Possible matches are labeled.
Loading coverage…
Where it goes next
While a bill can still move, the questions are about people and money.